These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
303 related items for PubMed ID: 18033780
1. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780 [Abstract] [Full Text] [Related]
2. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Entenza JM, Moreillon P. Int J Antimicrob Agents; 2009 Jul; 34(1):8.e1-9. PubMed ID: 19162449 [Abstract] [Full Text] [Related]
3. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. J Antimicrob Chemother; 2006 Mar; 57(3):573-6. PubMed ID: 16431863 [Abstract] [Full Text] [Related]
4. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565 [Abstract] [Full Text] [Related]
5. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST) Group. Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561 [Abstract] [Full Text] [Related]
6. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563 [Abstract] [Full Text] [Related]
7. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007. Garrison MW, Mutters R, Dowzicky MJ. Diagn Microbiol Infect Dis; 2009 Nov; 65(3):288-99. PubMed ID: 19733459 [Abstract] [Full Text] [Related]
8. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints. Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Study Group. Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184 [Abstract] [Full Text] [Related]
9. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567 [Abstract] [Full Text] [Related]
10. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992 [Abstract] [Full Text] [Related]
11. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205 [Abstract] [Full Text] [Related]
13. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy. Roveta S, Marchese A, Debbia EA. Chemotherapy; 2008 Aug; 54(1):43-9. PubMed ID: 18073470 [Abstract] [Full Text] [Related]
14. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin. Schmalreck AF, Wildfeuer A. Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754 [Abstract] [Full Text] [Related]
15. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005]. Yang QW, Xu YC, Chen MJ, Hu YJ, Ni YX, Sun JY, Yu YS, Kong HS, He L, Wu WY, Ye HF, Yang YM, Zhu LN, Guo SH, Ji P, Zhu ZH, Ren JK, Zhang LX, Sun ZY, Zhu XH, Tong MQ, Zhao WS, Mei YN, Liu Y, Zhang ZJ, Duan Q, Li D, Liu PP, Wang J, Han LX, Wang H, Xie XL. Zhonghua Yi Xue Za Zhi; 2007 Oct 23; 87(39):2753-8. PubMed ID: 18167265 [Abstract] [Full Text] [Related]
17. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C, Argentinean Tigecycline Surveillance Group. Chemotherapy; 2009 Oct 23; 55(1):20-7. PubMed ID: 18974645 [Abstract] [Full Text] [Related]
18. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Diagn Microbiol Infect Dis; 2005 Jul 23; 52(3):195-201. PubMed ID: 16105564 [Abstract] [Full Text] [Related]
20. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Zhanel GG, DeCorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA, Lagacé-Wiens P, Walkty A, Mulvey MR, Hoban DJ, Canadian Antimicrobial Resistance Alliance. Diagn Microbiol Infect Dis; 2008 Sep 23; 62(1):67-80. PubMed ID: 18513913 [Abstract] [Full Text] [Related] Page: [Next] [New Search]